Stem definition | Drug id | CAS RN |
---|---|---|
aromatic ring -CH(-OH)-CH2-NH-R | 1531 | 36894-69-6 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
0.60 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 16 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 104.53 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 4.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 23 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 1, 1984 | FDA | CNTY LINE PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 561.28 | 12.88 | 387 | 15472 | 124473 | 53208734 |
Premature delivery | 475.17 | 12.88 | 205 | 15654 | 25899 | 53307308 |
Maternal exposure during pregnancy | 421.80 | 12.88 | 357 | 15502 | 155282 | 53177925 |
Pre-eclampsia | 375.28 | 12.88 | 128 | 15731 | 8519 | 53324688 |
Premature baby | 206.63 | 12.88 | 106 | 15753 | 19695 | 53313512 |
Hypertension | 193.17 | 12.88 | 283 | 15576 | 225148 | 53108059 |
Caesarean section | 175.74 | 12.88 | 91 | 15768 | 17229 | 53315978 |
Low birth weight baby | 167.18 | 12.88 | 65 | 15794 | 6272 | 53326935 |
Foetal exposure during pregnancy | 153.86 | 12.88 | 107 | 15752 | 34608 | 53298599 |
Premature labour | 84.27 | 12.88 | 50 | 15809 | 12312 | 53320895 |
Blood pressure inadequately controlled | 80.88 | 12.88 | 36 | 15823 | 4875 | 53328332 |
Foetal growth restriction | 73.62 | 12.88 | 38 | 15821 | 7136 | 53326071 |
Foetal death | 66.84 | 12.88 | 39 | 15820 | 9308 | 53323899 |
Diabetes mellitus inadequate control | 65.45 | 12.88 | 45 | 15814 | 14265 | 53318942 |
Oligohydramnios | 61.82 | 12.88 | 32 | 15827 | 6044 | 53327163 |
Exomphalos | 61.55 | 12.88 | 17 | 15842 | 552 | 53332655 |
Rheumatoid arthritis | 61.37 | 12.88 | 10 | 15849 | 314521 | 53018686 |
Patent ductus arteriosus | 60.89 | 12.88 | 28 | 15831 | 4090 | 53329117 |
HELLP syndrome | 60.76 | 12.88 | 19 | 15840 | 957 | 53332250 |
Pregnancy | 57.30 | 12.88 | 58 | 15801 | 31383 | 53301824 |
Phaeochromocytoma | 56.83 | 12.88 | 16 | 15843 | 558 | 53332649 |
Multiple drug therapy | 53.34 | 12.88 | 19 | 15840 | 1434 | 53331773 |
Proteinuria | 51.86 | 12.88 | 43 | 15816 | 18025 | 53315182 |
Eclampsia | 49.12 | 12.88 | 13 | 15846 | 358 | 53332849 |
Exercise tolerance decreased | 45.72 | 12.88 | 25 | 15834 | 5270 | 53327937 |
Blood pressure increased | 44.45 | 12.88 | 116 | 15743 | 140363 | 53192844 |
Haemangioma congenital | 40.80 | 12.88 | 12 | 15847 | 490 | 53332717 |
Live birth | 39.44 | 12.88 | 34 | 15825 | 15025 | 53318182 |
Normal newborn | 38.67 | 12.88 | 25 | 15834 | 7154 | 53326053 |
Gestational diabetes | 38.47 | 12.88 | 26 | 15833 | 8013 | 53325194 |
Abortion spontaneous | 37.51 | 12.88 | 57 | 15802 | 46578 | 53286629 |
Hypotension | 35.11 | 12.88 | 159 | 15700 | 253917 | 53079290 |
Gestational hypertension | 34.92 | 12.88 | 16 | 15843 | 2317 | 53330890 |
Pulmonary oedema | 34.13 | 12.88 | 59 | 15800 | 53664 | 53279543 |
Posterior reversible encephalopathy syndrome | 33.51 | 12.88 | 32 | 15827 | 16128 | 53317079 |
Norepinephrine increased | 33.09 | 12.88 | 7 | 15852 | 70 | 53333137 |
Drug intolerance | 33.07 | 12.88 | 10 | 15849 | 205483 | 53127724 |
Frequent bowel movements | 32.69 | 12.88 | 30 | 15829 | 14382 | 53318825 |
Hypertensive crisis | 32.53 | 12.88 | 30 | 15829 | 14476 | 53318731 |
Foetal distress syndrome | 32.39 | 12.88 | 13 | 15846 | 1362 | 53331845 |
BRASH syndrome | 31.48 | 12.88 | 8 | 15851 | 187 | 53333020 |
Intestinal malrotation | 29.89 | 12.88 | 9 | 15850 | 399 | 53332808 |
Hyperkalaemia | 29.89 | 12.88 | 56 | 15803 | 54200 | 53279007 |
Endometritis | 28.73 | 12.88 | 11 | 15848 | 1017 | 53332190 |
Cardiac failure congestive | 28.70 | 12.88 | 76 | 15783 | 92681 | 53240526 |
Perinatal stroke | 28.68 | 12.88 | 5 | 15854 | 15 | 53333192 |
Nipple pain | 28.50 | 12.88 | 8 | 15851 | 276 | 53332931 |
Stillbirth | 27.88 | 12.88 | 20 | 15839 | 6777 | 53326430 |
Cerebrovascular accident | 27.45 | 12.88 | 81 | 15778 | 105093 | 53228114 |
Maternal drugs affecting foetus | 26.69 | 12.88 | 18 | 15841 | 5528 | 53327679 |
Myocardial infarction | 26.39 | 12.88 | 77 | 15782 | 99277 | 53233930 |
Hypermagnesaemia | 25.41 | 12.88 | 10 | 15849 | 995 | 53332212 |
Cardiac arrest | 25.27 | 12.88 | 73 | 15786 | 93594 | 53239613 |
Bradycardia | 24.87 | 12.88 | 61 | 15798 | 70995 | 53262212 |
Arthropathy | 24.41 | 12.88 | 6 | 15853 | 141447 | 53191760 |
Mental status changes | 23.25 | 12.88 | 42 | 15817 | 39529 | 53293678 |
Neonatal respiratory distress syndrome | 23.03 | 12.88 | 13 | 15846 | 2914 | 53330293 |
Hydrocephalus | 22.85 | 12.88 | 16 | 15843 | 5220 | 53327987 |
Neuromuscular blockade | 22.69 | 12.88 | 7 | 15852 | 337 | 53332870 |
Placental insufficiency | 22.38 | 12.88 | 10 | 15849 | 1366 | 53331841 |
Induced labour | 22.05 | 12.88 | 9 | 15850 | 984 | 53332223 |
Cerebral haemorrhage | 21.80 | 12.88 | 35 | 15824 | 29961 | 53303246 |
Haemodynamic instability | 21.69 | 12.88 | 19 | 15840 | 8575 | 53324632 |
Pain | 21.52 | 12.88 | 96 | 15763 | 588302 | 52744905 |
Joint swelling | 21.30 | 12.88 | 23 | 15836 | 234615 | 53098592 |
Contraindicated product administered | 21.10 | 12.88 | 7 | 15852 | 135622 | 53197585 |
Phaeochromocytoma crisis | 20.74 | 12.88 | 6 | 15853 | 231 | 53332976 |
Neonatal respiratory distress | 20.38 | 12.88 | 6 | 15853 | 246 | 53332961 |
Glomerulonephritis rapidly progressive | 20.13 | 12.88 | 8 | 15851 | 817 | 53332390 |
Angle closure glaucoma | 20.07 | 12.88 | 11 | 15848 | 2329 | 53330878 |
Respiratory distress | 19.99 | 12.88 | 36 | 15823 | 33791 | 53299416 |
Hypertrophic cardiomyopathy | 18.90 | 12.88 | 9 | 15850 | 1422 | 53331785 |
Withdrawal hypertension | 18.64 | 12.88 | 5 | 15854 | 145 | 53333062 |
Arthralgia | 18.41 | 12.88 | 68 | 15791 | 439715 | 52893492 |
Sinusitis | 18.30 | 12.88 | 14 | 15845 | 168550 | 53164657 |
Infusion related reaction | 18.18 | 12.88 | 12 | 15847 | 155945 | 53177262 |
Medication error | 18.14 | 12.88 | 36 | 15823 | 36329 | 53296878 |
Ultrasound uterus abnormal | 17.81 | 12.88 | 4 | 15855 | 54 | 53333153 |
Small for dates baby | 17.63 | 12.88 | 12 | 15847 | 3740 | 53329467 |
Haemorrhagic transformation stroke | 17.25 | 12.88 | 8 | 15851 | 1190 | 53332017 |
Nephrogenic systemic fibrosis | 17.23 | 12.88 | 13 | 15846 | 4754 | 53328453 |
Alopecia | 17.17 | 12.88 | 27 | 15832 | 234556 | 53098651 |
Renal failure | 16.97 | 12.88 | 75 | 15784 | 118377 | 53214830 |
Treatment noncompliance | 16.84 | 12.88 | 33 | 15826 | 33002 | 53300205 |
Alveolar capillary dysplasia | 16.54 | 12.88 | 3 | 15856 | 12 | 53333195 |
Haemorrhage intracranial | 16.32 | 12.88 | 20 | 15839 | 13332 | 53319875 |
Kidney transplant rejection | 16.30 | 12.88 | 12 | 15847 | 4232 | 53328975 |
Post transplant lymphoproliferative disorder | 15.98 | 12.88 | 12 | 15847 | 4359 | 53328848 |
Pulseless electrical activity | 15.91 | 12.88 | 15 | 15844 | 7439 | 53325768 |
Congenital intestinal malformation | 15.83 | 12.88 | 3 | 15856 | 16 | 53333191 |
Gingival hypertrophy | 15.49 | 12.88 | 8 | 15851 | 1503 | 53331704 |
Gastrointestinal disorder | 15.17 | 12.88 | 4 | 15855 | 90000 | 53243207 |
Hypotonia neonatal | 14.94 | 12.88 | 7 | 15852 | 1066 | 53332141 |
Malignant hypertension | 14.74 | 12.88 | 7 | 15852 | 1099 | 53332108 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 14.70 | 12.88 | 9 | 15850 | 2342 | 53330865 |
Autoimmune nephritis | 14.51 | 12.88 | 5 | 15854 | 342 | 53332865 |
Decreased ventricular preload | 14.46 | 12.88 | 3 | 15856 | 27 | 53333180 |
Thymus hypoplasia | 14.37 | 12.88 | 3 | 15856 | 28 | 53333179 |
Apgar score low | 14.31 | 12.88 | 6 | 15853 | 702 | 53332505 |
Glossodynia | 14.21 | 12.88 | 6 | 15853 | 100285 | 53232922 |
Tongue oedema | 14.03 | 12.88 | 11 | 15848 | 4256 | 53328951 |
Dilatation intrahepatic duct acquired | 13.89 | 12.88 | 6 | 15853 | 756 | 53332451 |
Central nervous system lesion | 13.70 | 12.88 | 16 | 15843 | 10146 | 53323061 |
Hepatitis acute | 13.66 | 12.88 | 15 | 15844 | 8901 | 53324306 |
Oncologic complication | 13.61 | 12.88 | 4 | 15855 | 163 | 53333044 |
Infection | 13.39 | 12.88 | 19 | 15840 | 172186 | 53161021 |
Intraventricular haemorrhage | 13.33 | 12.88 | 8 | 15851 | 2010 | 53331197 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal exposure during pregnancy | 354.78 | 14.52 | 190 | 8933 | 41111 | 32463292 |
Premature baby | 314.15 | 14.52 | 136 | 8987 | 18382 | 32486021 |
Low birth weight baby | 237.66 | 14.52 | 85 | 9038 | 6909 | 32497494 |
Foetal growth restriction | 79.66 | 14.52 | 33 | 9090 | 3979 | 32500424 |
Polydactyly | 77.90 | 14.52 | 24 | 9099 | 1221 | 32503182 |
Foetal disorder | 66.29 | 14.52 | 19 | 9104 | 751 | 32503652 |
Neutropenia neonatal | 59.93 | 14.52 | 17 | 9106 | 647 | 32503756 |
Lichen planus | 54.59 | 14.52 | 17 | 9106 | 896 | 32503507 |
Zoonotic bacterial infection | 52.50 | 14.52 | 10 | 9113 | 59 | 32504344 |
Mycobacterium marinum infection | 51.70 | 14.52 | 13 | 9110 | 309 | 32504094 |
Hypertension | 48.31 | 14.52 | 111 | 9012 | 131639 | 32372764 |
Anhedonia | 45.98 | 14.52 | 29 | 9094 | 8435 | 32495968 |
Maternal exposure during pregnancy | 39.96 | 14.52 | 21 | 9102 | 4336 | 32500067 |
Choreoathetosis | 36.52 | 14.52 | 13 | 9110 | 1038 | 32503365 |
Congenital oesophageal anomaly | 36.50 | 14.52 | 8 | 9115 | 102 | 32504301 |
Neonatal respiratory distress | 35.48 | 14.52 | 11 | 9112 | 571 | 32503832 |
Cardiac arrest | 34.84 | 14.52 | 81 | 9042 | 96695 | 32407708 |
Apgar score low | 33.92 | 14.52 | 12 | 9111 | 941 | 32503462 |
Injury | 33.37 | 14.52 | 36 | 9087 | 22209 | 32482194 |
Neonatal hypoxia | 31.56 | 14.52 | 9 | 9114 | 349 | 32504054 |
Fear | 29.78 | 14.52 | 25 | 9098 | 11294 | 32493109 |
Patent ductus arteriosus | 27.78 | 14.52 | 15 | 9108 | 3270 | 32501133 |
Hypotension | 27.77 | 14.52 | 127 | 8996 | 215983 | 32288420 |
Mental status changes | 27.40 | 14.52 | 43 | 9080 | 38294 | 32466109 |
Newborn persistent pulmonary hypertension | 26.66 | 14.52 | 6 | 9117 | 87 | 32504316 |
Nephrogenic systemic fibrosis | 26.40 | 14.52 | 16 | 9107 | 4336 | 32500067 |
Chronic kidney disease | 26.06 | 14.52 | 43 | 9080 | 39932 | 32464471 |
Polyhydramnios | 25.08 | 14.52 | 7 | 9116 | 251 | 32504152 |
Hydrops foetalis | 24.76 | 14.52 | 7 | 9116 | 263 | 32504140 |
Bradycardia | 24.76 | 14.52 | 59 | 9064 | 71503 | 32432900 |
Renal injury | 24.49 | 14.52 | 23 | 9100 | 12032 | 32492371 |
Emotional distress | 23.77 | 14.52 | 26 | 9097 | 16280 | 32488123 |
Cardiac failure congestive | 23.18 | 14.52 | 64 | 9059 | 84788 | 32419615 |
Bradycardia foetal | 22.77 | 14.52 | 7 | 9116 | 353 | 32504050 |
Cleft lip and palate | 22.53 | 14.52 | 7 | 9116 | 366 | 32504037 |
Maternal drugs affecting foetus | 21.60 | 14.52 | 14 | 9109 | 4263 | 32500140 |
Malignant hypertension | 21.59 | 14.52 | 8 | 9115 | 716 | 32503687 |
Familial periodic paralysis | 20.94 | 14.52 | 5 | 9118 | 95 | 32504308 |
Posterior reversible encephalopathy syndrome | 20.87 | 14.52 | 19 | 9104 | 9557 | 32494846 |
Trisomy 18 | 20.79 | 14.52 | 6 | 9117 | 243 | 32504160 |
Pyelocaliectasis | 20.27 | 14.52 | 9 | 9114 | 1283 | 32503120 |
Hypertensive crisis | 20.21 | 14.52 | 18 | 9105 | 8799 | 32495604 |
Haemorrhagic transformation stroke | 19.84 | 14.52 | 9 | 9114 | 1349 | 32503054 |
Cerebrovascular accident | 19.64 | 14.52 | 61 | 9062 | 86259 | 32418144 |
Bronchopulmonary dysplasia | 19.58 | 14.52 | 7 | 9116 | 566 | 32503837 |
Complications of transplanted kidney | 19.15 | 14.52 | 13 | 9110 | 4277 | 32500126 |
Renal transplant failure | 18.26 | 14.52 | 8 | 9115 | 1106 | 32503297 |
Neonatal cholestasis | 18.04 | 14.52 | 4 | 9119 | 54 | 32504349 |
Trigemino-cardiac reflex | 17.68 | 14.52 | 5 | 9118 | 188 | 32504215 |
Exposure during pregnancy | 17.59 | 14.52 | 17 | 9106 | 9212 | 32495191 |
Rickets | 17.40 | 14.52 | 4 | 9119 | 64 | 32504339 |
Zoonosis | 16.17 | 14.52 | 3 | 9120 | 15 | 32504388 |
Foetal death | 16.06 | 14.52 | 5 | 9118 | 263 | 32504140 |
Cardiomyopathy | 15.89 | 14.52 | 21 | 9102 | 15992 | 32488411 |
Ventricular septal defect | 15.86 | 14.52 | 11 | 9112 | 3746 | 32500657 |
Skin fibrosis | 15.32 | 14.52 | 7 | 9116 | 1067 | 32503336 |
Blood pressure increased | 15.28 | 14.52 | 53 | 9070 | 79301 | 32425102 |
Gastrointestinal tract mucosal pigmentation | 14.53 | 14.52 | 5 | 9118 | 361 | 32504042 |
Source | Code | Description |
---|---|---|
ATC | C07AG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Alpha and beta blocking agents |
ATC | C07BG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Alpha and beta blocking agents and thiazides |
ATC | C07CG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND OTHER DIURETICS Alpha and beta blocking agents and other diuretics |
FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
FDA EPC | N0000175556 | beta-Adrenergic Blocker |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D058668 | Adrenergic alpha-1 Receptor Antagonists |
MeSH PA | D000317 | Adrenergic alpha-Antagonists |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D000319 | Adrenergic beta-Antagonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35530 | beta-adrenoceptor antagonists |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:37890 | alpha-adrenoceptor antagonists |
CHEBI has role | CHEBI:66991 | sympatholytics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Angina pectoris | off-label use | 194828000 | |
Pheochromocytoma Adjunct Therapy | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Bronchospasm | contraindication | 4386001 | |
Hypercholesterolemia | contraindication | 13644009 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Complete atrioventricular block | contraindication | 27885002 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Depressive disorder | contraindication | 35489007 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Sinus bradycardia | contraindication | 49710005 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Pulmonary emphysema | contraindication | 87433001 | |
Cardiogenic shock | contraindication | 89138009 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hypomagnesemia | contraindication | 190855004 | |
Partial atrioventricular block | contraindication | 195039008 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Intraoperative floppy iris syndrome | contraindication | 418801006 | |
Azotemia | contraindication | 445009001 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.81 | acidic |
pKa2 | 12.65 | acidic |
pKa3 | 8.23 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.23 | DRUG MATRIX | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.96 | DRUG MATRIX | CHEMBL | |||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.12 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.48 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.65 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.71 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.89 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.64 | DRUG MATRIX | ||||
Alpha-1B adrenergic receptor | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.24 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.41 | CHEMBL | |||||
CAAX prenyl protease 1 | Enzyme | AC50 | 5.11 | CHEMBL | |||||
CAAX prenyl protease 2 | Enzyme | AC50 | 4.82 | CHEMBL |
ID | Source |
---|---|
4019797 | VUID |
N0000147886 | NUI |
D00600 | KEGG_DRUG |
32780-64-6 | SECONDARY_CAS_RN |
4018799 | VANDF |
4019797 | VANDF |
C0022860 | UMLSCUI |
CHEBI:6343 | CHEBI |
CHEMBL429 | ChEMBL_ID |
CHEMBL1200323 | ChEMBL_ID |
DB00598 | DRUGBANK_ID |
D007741 | MESH_DESCRIPTOR_UI |
3869 | PUBCHEM_CID |
7207 | IUPHAR_LIGAND_ID |
3941 | INN_ID |
R5H8897N95 | UNII |
202693 | RXNORM |
11828 | MMSL |
201477 | MMSL |
4950 | MMSL |
d00016 | MMSL |
001839 | NDDF |
004368 | NDDF |
372750000 | SNOMEDCT_US |
46547007 | SNOMEDCT_US |
50627005 | SNOMEDCT_US |
CHEMBL1204165 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9320 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9363 | INJECTION | 1 mg | INTRAVENOUS | NDA | 23 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9364 | INJECTION | 1 mg | INTRAVENOUS | NDA | 23 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9365 | INJECTION | 1 mg | INTRAVENOUS | NDA | 23 sections |
Labetalol HCl in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9366 | INJECTION | 1 mg | INTRAVENOUS | NDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9622 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9623 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0010 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0117 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0118 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2267 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2339 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0605 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0606 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0607 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8130 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8131 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5928 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5929 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5930 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7109 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 19 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7110 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 19 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7111 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 19 sections |
Labetalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-641 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
Labetalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-642 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
Labetalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-643 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-711 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 24 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-712 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 24 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-713 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 24 sections |
LABETALOL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-994 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 24 sections |